Data / Form D filings / Gilgamesh Pharma Inc.
Gilgamesh Pharma Inc.: Form D filings
Gilgamesh Pharma Inc., a pharmaceuticals company in New York, NY, filed 4 Form D notices with the SEC in 2026. The latest, on March 31, 2026, reports $2.3 million sold of a $15 million offering to 3 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 113 UNIVERSITY PLACE, SUITE 1019, New York, NY, 10003
- Phone
- (929) 723-4861
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2025
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2107396
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | New notice | $15,000,000 | $2,250,000 | $12,750,000 | 3 | Mar 27, 2026 | sec.gov |
| Mar 24, 2026 | New notice | $60,000,000 | $60,000,000 | 40 | Mar 9, 2026 | sec.gov | |
| Feb 4, 2026 | New notice | $6,090,946 | $6,090,946 | 9 | Jan 2, 2026 | sec.gov | |
| Feb 4, 2026 | New notice | $4,366,118 | $0 | $4,366,118 | 8 | Yet to occur | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jonathan Sporn | Executive Officer, Director | |
| Andrew Kruegel | Executive Officer, Director | |
| Amy Kruse | Director | |
| Zia Huque | Director | |
| Robert Berman | Director | |
| Phil Skolnick | Director |
Other pharmaceuticals companies in New York that filed recently
- Pierrepont Therapeutics, Inc. $2.4 million · Sep 22, 2026
Every Form D from the week of Mar 30, 2026 · All recent filings in New York · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Gilgamesh Pharma Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.